Report cover image

Recombinant Proteins Market by Product (Adhesion Molecules & Receptors, Growth Factors & Chemokines, Immune Response Proteins), Services (Cloning, Expression, Purification), End-User, Function - Global Forecast 2023-2030

Publisher 360iResearch
Published Oct 05, 2023
Length 186 Pages
SKU # IRE18312903

Description

Recombinant Proteins Market by Product (Adhesion Molecules & Receptors, Growth Factors & Chemokines, Immune Response Proteins), Services (Cloning, Expression, Purification), End-User, Function - Global Forecast 2023-2030


The Recombinant Proteins Market is projected to reach USD 13.04 billion by 2030 from USD 4.36 billion in 2022, at a CAGR of 14.67% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Recombinant Proteins Market.
  • Based on Product, market is studied across Adhesion Molecules & Receptors, Growth Factors & Chemokines, Immune Response Proteins, Kinase Proteins, Membrane Proteins, Recombinant Metabolic Enzymes, Regulatory Proteins, and Structural Proteins. The Growth Factors & Chemokines commanded largest market share of 23.76% in 2022, followed by Membrane Proteins.
  • Based on Services, market is studied across Cloning, Expression, and Purification. The Expression commanded largest market share of 39.54% in 2022, followed by Purification.
  • Based on End-User, market is studied across Academic Research Institutes, Contract Research Organizations & Contract Manufacturing Organizations, and Pharmaceutical & Biopharmaceutical Companies. The Pharmaceutical & Biopharmaceutical Companies commanded largest market share of 54.54% in 2022, followed by Contract Research Organizations & Contract Manufacturing Organizations.
  • Based on Function, market is studied across Diagnostics and Drug Discovery & Development. The Drug Discovery & Development is further studied across Biologics, Cell & Gene Therapy, and Vaccines. The Drug Discovery & Development commanded largest market share of 67.54% in 2022, followed by Diagnostics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 41.52% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Recombinant Proteins Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Recombinant Proteins Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Recombinant Proteins Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Agilent Technologies, Inc., Bhat Bio-tech India Private Limited, Bio-Rad Laboratories, Inc., Biogen Inc., BioLegend, Inc. by PerkinElmer, Inc., Biologics International Corp, BPS Bioscience, Inc., Bristol-Myers Squibb Company, Creative BioMart Inc., Croyez Bioscience Co., Ltd., Eli Lilly and Company, Enzo Life Sciences, Inc., Fortis Life Sciences LLC, GenScript Biotech Corporation, GeoVax Labs, Inc., Hzymes Biotech, Johnson & Johnson Services, Inc., Laurus Labs Limited, LenioBio GmbH, Lonza Group AG, Marin Biologic Laboratories, Inc., Merck KGaA, Meridian Bioscience, Inc. by SD Biosensor Inc., Miltenyi Biotec B.V. & Co. KG, Novartis AG, ProMab Biotechnologies, Inc., Proteintech Group, Inc., Proteos, Inc., R&D Systems, Inc. by Bio-Techne Corporation, Sanofi S.A., Sartorius AG, Selvita S.A., Sino Biological, Inc., SK bioscience, Takara Bio Inc., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific, Inc..

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Recombinant Proteins Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Recombinant Proteins Market?
  3. What is the competitive strategic window for identifying opportunities in the Recombinant Proteins Market?
  4. What are the latest technology trends and regulatory frameworks in the Recombinant Proteins Market?
  5. What is the market share of the leading vendors in the Recombinant Proteins Market?
  6. Which modes and strategic moves are suitable for entering the Recombinant Proteins Market?


Please Note: PDF & Excel + Online Access - 1 Year

Table of Contents

186 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Recombinant Proteins Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising focus on personalized medicine & protein therapeutics in the consumers
5.1.1.2. High prevalence of infectious & chronic diseases among geriatric population and children
5.1.1.3. Surging inclination of demand toward biologics and biosimilars proteins
5.1.2. Restraints
5.1.2.1. Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
5.1.3. Opportunities
5.1.3.1. Increasing focus on biomarker discovery and surging investments recombinant protein development
5.1.3.2. Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
5.1.4. Challenges
5.1.4.1. Availability of alternative products and several issues in production
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.3.1. Increase in research spending coupled with healthcare infrastructure across Americas
5.3.2. Prevalence of chronic diseases and significant investments in medical research in the APAC region
5.3.3. Expanding drug manufacturing facilities and regulatory guidelines for recombinant protein in the EMEA region.
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Recombinant Proteins Market, by Product
6.1. Introduction
6.2. Adhesion Molecules & Receptors
6.3. Growth Factors & Chemokines
6.4. Immune Response Proteins
6.5. Kinase Proteins
6.6. Membrane Proteins
6.7. Recombinant Metabolic Enzymes
6.8. Regulatory Proteins
6.9. Structural Proteins
7. Recombinant Proteins Market, by Services
7.1. Introduction
7.2. Cloning
7.3. Expression
7.4. Purification
8. Recombinant Proteins Market, by End-User
8.1. Introduction
8.2. Academic Research Institutes
8.3. Contract Research Organizations & Contract Manufacturing Organizations
8.4. Pharmaceutical & Biopharmaceutical Companies
9. Recombinant Proteins Market, by Function
9.1. Introduction
9.2. Diagnostics
9.3. Drug Discovery & Development
9.4.1. Biologics
9.4.2. Cell & Gene Therapy
9.4.3. Vaccines
10. Americas Recombinant Proteins Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Recombinant Proteins Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Recombinant Proteins Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Merger & Acquisition
13.3.1.1. Fortis Life Sciences acquires International Point of Care
13.3.1.2. Fujifilm to Acquire Shenandoah Biotechnology, Leading Manufacturer of Recombinant Proteins
13.3.1.3. Thermo Fisher Scientific Completes Acquisition of PeproTech, engaged in Recombinant Proteins
13.3.2. Agreement, Collaboration, & Partnership
13.3.2.1. iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein
13.3.2.2. Curia Expands Cell Line Development Offering with CHOZN Platform
13.3.3. New Product Launch & Enhancement
13.3.3.1. Shenandoah Biotechnology Introduces Expanded Range of CTGrade Recombinant Proteins Manufactured Following cGMP Practices
13.3.4. Investment & Funding
13.3.4.1. Biovian Invests Over EUR 50M in Manufacturing Facility in Finland
13.3.4.2. Future Fields raises USD 11.2 million to scale up fruit flies for recombinant protein production
13.3.5. Award, Recognition, & Expansion
13.3.5.1. Merck’s Biodevelopment Centre Expansion, Martillac, France
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abcam PLC
14.1.2. Abnova Corporation
14.1.3. Agilent Technologies, Inc.
14.1.4. Bhat Bio-tech India Private Limited
14.1.5. Bio-Rad Laboratories, Inc.
14.1.6. Biogen Inc.
14.1.7. BioLegend, Inc. by PerkinElmer, Inc.
14.1.8. Biologics International Corp
14.1.9. BPS Bioscience, Inc.
14.1.10. Bristol-Myers Squibb Company
14.1.11. Creative BioMart Inc.
14.1.12. Croyez Bioscience Co., Ltd.
14.1.13. Eli Lilly and Company
14.1.14. Enzo Life Sciences, Inc.
14.1.15. Fortis Life Sciences LLC
14.1.16. GenScript Biotech Corporation
14.1.17. GeoVax Labs, Inc.
14.1.18. Hzymes Biotech
14.1.19. Johnson & Johnson Services, Inc.
14.1.20. Laurus Labs Limited
14.1.21. LenioBio GmbH
14.1.22. Lonza Group AG
14.1.23. Marin Biologic Laboratories, Inc.
14.1.24. Merck KGaA
14.1.25. Meridian Bioscience, Inc. by SD Biosensor Inc.
14.1.26. Miltenyi Biotec B.V. & Co. KG
14.1.27. Novartis AG
14.1.28. ProMab Biotechnologies, Inc.
14.1.29. Proteintech Group, Inc.
14.1.30. Proteos, Inc.
14.1.31. R&D Systems, Inc. by Bio-Techne Corporation
14.1.32. Sanofi S.A.
14.1.33. Sartorius AG
14.1.34. Selvita S.A.
14.1.35. Sino Biological, Inc.
14.1.36. SK bioscience
14.1.37. Takara Bio Inc.
14.1.38. Takeda Pharmaceutical Company Limited
14.1.39. Thermo Fisher Scientific, Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us